Physician profile
Lawrence Dinenberg
NPI 1952479164
$306.62
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $19.36 · 2021: $19.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $77.56 | 2019-2021 | |
| Novo Nordisk INC | $73.23 | 2019-2020 | |
| Antares Pharma, INC. | $44.36 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.76 | 2019 | |
| Amag Pharmaceuticals, INC. | $20.99 | 2019 | |
| Amarin Pharma, INC. | $20.48 | 2019 | |
| Assertio Therapeutics, INC. | $19.31 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.90 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $14.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Dinenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.